Patent ID: 8128931

Claim:
A method of treating a subject with a primary or metastatic carcinoma of the lung or pleura with or without pleural effusion comprising administering to said subject in need thereof parenterally by infusion or injection a tumoricidally effective amount of a composition consisting of: (i) a native staphylococcal enterotoxin or streptococcal pyrogenic exotoxin protein which native protein: (a) has the biological activity of stimulating T cell mitogenesis via a T cell receptor νβ region; or (ii) a biologically active homologue or fragment of a native staphylococcal enterotoxin or streptococcal pyrogenic exotoxin, which homologue or fragment: (a) has the biological activity of stimulating T cell mitogenesis via a T cell receptor νβ region and (b) has sequence homology characterized as a z value exceeding 13 when the sequence of the homologue or said fragment is compared to the sequence of a native staphylococcal enterotoxin or a native streptococcal pyrogenic exotoxin, determined by FASTA analysis using gap penalties of −12 and −2, Blosum 50 matrix and Swiss-PROT or PIR database; or (iii) a biologically active fusion protein having said biological activity and said sequence homology, comprising (A) said homologue, (B) a native staphylococcal enterotoxin, (C) a native streptococcal pyrogenic exotoxin, or (D) a biologically active fragment of said homologue, said native enterotoxin or said native exotoxin, fused to a peptide or polypeptide fusion partner, wherein a chemotherapeutic drug or drugs is/are adminstered parenterally by infusion or injection before, together with or after administration of said enterotoxin or exotoxin composition.